Passage Bio Stock Cash And Equivalents
| PASG Stock | USD 0.62 0.11 21.57% |
Passage Bio fundamentals help investors to digest information that contributes to Passage Bio's financial success or failures. It also enables traders to predict the movement of Passage Stock. The fundamental analysis module provides a way to measure Passage Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Passage Bio stock.
Passage | Cash And Equivalents |
Passage Bio Company Cash And Equivalents Analysis
Passage Bio's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Passage Bio Cash And Equivalents | 239.25 M |
Most of Passage Bio's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Passage Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Passage Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Passage Bio is extremely important. It helps to project a fair market value of Passage Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Passage Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Passage Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Passage Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Passage Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Passage Bio has 239.25 M in Cash And Equivalents. This is 70.85% lower than that of the Biotechnology sector and 46.49% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 91.15% higher than that of the company.
Passage Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Passage Bio's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Passage Bio could also be used in its relative valuation, which is a method of valuing Passage Bio by comparing valuation metrics of similar companies.Passage Bio is currently under evaluation in cash and equivalents category among its peers.
Passage Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (27.82 M) | ||||
| Shares Outstanding | 61.77 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 59.68 % | ||||
| Number Of Shares Shorted | 1.64 M | ||||
| Price To Book | 0.43 X | ||||
| EBITDA | (98.34 M) | ||||
| Net Income | (102.06 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 26.29 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (78.26 M) | ||||
| Short Ratio | 6.61 X | ||||
| Earnings Per Share | (1.17) X | ||||
| Target Price | 7.67 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.2 | ||||
| Market Capitalization | 31.19 M | ||||
| Total Asset | 150.54 M | ||||
| Retained Earnings | (594.47 M) | ||||
| Working Capital | 101.62 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
| Net Asset | 150.54 M |
About Passage Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Passage Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Passage Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Passage Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Passage Bio Piotroski F Score and Passage Bio Altman Z Score analysis. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.